Youwei Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Youwei Xu has a total of 259 co-authors. Here are the top co-authors by number of shared publications:
- H. Eric Xu
CAS Key Laboratory of Receptor Research, Center for Structure and Function of Drug Targets, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
33 shared publications Qingning Yuan
Research Center for Medicinal Structural Biology, National Research Center for Translational Medicine at Shanghai, State Key Laboratory of Medical Genomics, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
18 shared publicationsKai Wu
The State Key Laboratory of Drug Research, Center for Structure and Function of Drug Targets, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
15 shared publicationsWen Hu
The State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
13 shared publications- Xinheng He
The State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
13 shared publications - Yi Jiang
School of Life Science and Technology, ShanghaiTech University, Shanghai, China
12 shared publications
Latest Publications
- 23 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (43) , eaeh3401
Multiple allosteric sites allow for synergistic enhancement of GPCR signaling
Allosteric modulation of G protein–coupled receptors (GPCRs) offers promising therapeutic opportunities. Although multiple allosteric binding sites have been identified in GPCRs, whether and how these spatially distinct sites cooperate to regulate receptor activation remain poorly understood. Here, we elucidate the molecular mechanism of cooperative multisite allostery in the dopamine D1 receptor (D1R). We developed two novel D1R positive allosteric modulators (PAMs), UNC9815 and UNC10062, and used cryo–electron microscopy to structurally identify two previously uncharacterized D1R allosteric sites occupied by UNC9815/UNC10062 and another D1R PAM, BMS-A1. Both sites localize to the transmembrane helix (TM) 1 to 7 interface as vertically adjacent allosteric pockets organized in a spatially complementary manner. Our structures demonstrate the simultaneous binding of the chemically distinct PAMs (LY3154207, BMS-A1, and UNC9815/UNC10062) in three nonoverlapping pockets. Concurrent engagement of all three allosteric sites produces pronounced functional cooperativity, increasing dopamine potency by >1000-fold, thereby demonstrating that coordinated multisite modulation can achieve substantial pharmacological amplification beyond the limits imposed by single PAM administration. Molecular dynamics (MD) simulations revealed that multisite PAM engagement restricts intracellular loop 3 dynamics and stabilizes the TM7-NPxxY activation motif, effects not achieved by binding of LY3154207 alone, thereby biasing the receptor toward a more stabilized active conformation, and may also improve agonist potency by stabilizing extracellular loop 2. Together, these findings establish the structural framework for cooperative multisite allostery in a GPCR, revealing how distributed allosteric sites act in concert to amplify receptor activation and providing a conceptual foundation for developing innovative GPCR allosteric therapeutics.
- 23 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (43) , eaeh3401
Multiple allosteric sites allow for synergistic enhancement of GPCR signaling
Allosteric modulation of G protein–coupled receptors (GPCRs) offers promising therapeutic opportunities. Although multiple allosteric binding sites have been identified in GPCRs, whether and how these spatially distinct sites cooperate to regulate receptor activation remain poorly understood. Here, we elucidate the molecular mechanism of cooperative multisite allostery in the dopamine D1 receptor (D1R). We developed two novel D1R positive allosteric modulators (PAMs), UNC9815 and UNC10062, and used cryo–electron microscopy to structurally identify two previously uncharacterized D1R allosteric sites occupied by UNC9815/UNC10062 and another D1R PAM, BMS-A1. Both sites localize to the transmembrane helix (TM) 1 to 7 interface as vertically adjacent allosteric pockets organized in a spatially complementary manner. Our structures demonstrate the simultaneous binding of the chemically distinct PAMs (LY3154207, BMS-A1, and UNC9815/UNC10062) in three nonoverlapping pockets. Concurrent engagement of all three allosteric sites produces pronounced functional cooperativity, increasing dopamine potency by >1000-fold, thereby demonstrating that coordinated multisite modulation can achieve substantial pharmacological amplification beyond the limits imposed by single PAM administration. Molecular dynamics (MD) simulations revealed that multisite PAM engagement restricts intracellular loop 3 dynamics and stabilizes the TM7-NPxxY activation motif, effects not achieved by binding of LY3154207 alone, thereby biasing the receptor toward a more stabilized active conformation, and may also improve agonist potency by stabilizing extracellular loop 2. Together, these findings establish the structural framework for cooperative multisite allostery in a GPCR, revealing how distributed allosteric sites act in concert to amplify receptor activation and providing a conceptual foundation for developing innovative GPCR allosteric therapeutics.
- Open Access
- 9 October 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Lipid-organized tetramerization of PLPP1 defines the molecular basis of spatial lipid phosphate signaling
Bioactive lipid phosphates, such as lysophosphatidic acid (LPA) and sphingosine-1-phosphate, are potent membrane-embedded signals that regulate fundamental processes in development, immunity, and cancer. The termination of these signals is mediated by phospholipid phosphatases (PLPPs), yet the molecular principles governing their function at the membrane interface have remained poorly understood. Here we report high-resolution cryo-electron microscopy structures of human PLPP1 in apo (1.87 Å) and product-bound (2.21 Å) states. The structures reveal a highly ordered, C4-symmetric homotetramer with ordered lipid densities—including densities assigned to phosphatidylcholine, phosphatidic acid, and phosphatidylinositol-4,5-bisphosphate—at inter-subunit interfaces. Structure-guided mutagenesis shows that residues surrounding these interfacial lipid densities affect enzymatic activity, whereas oligomerization analysis indicates that activity loss does not simply correlate with tetramer disruption. The product-bound structure defines the catalytic pocket and a membrane-facing tunnel that suggests a possible route for LPA access, while electrophysiological recordings detected no PLPP1-associated ion conductance under the conditions tested. Together, these findings provide a structural framework for PLPP1 tetramer assembly, lipid phosphate hydrolysis, and product recognition.
- 9 October 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessLipid-organized tetramerization of PLPP1 defines the molecular basis of spatial lipid phosphate signaling
Bioactive lipid phosphates, such as lysophosphatidic acid (LPA) and sphingosine-1-phosphate, are potent membrane-embedded signals that regulate fundamental processes in development, immunity, and cancer. The termination of these signals is mediated by phospholipid phosphatases (PLPPs), yet the molecular principles governing their function at the membrane interface have remained poorly understood. Here we report high-resolution cryo-electron microscopy structures of human PLPP1 in apo (1.87 Å) and product-bound (2.21 Å) states. The structures reveal a highly ordered, C4-symmetric homotetramer with ordered lipid densities—including densities assigned to phosphatidylcholine, phosphatidic acid, and phosphatidylinositol-4,5-bisphosphate—at inter-subunit interfaces. Structure-guided mutagenesis shows that residues surrounding these interfacial lipid densities affect enzymatic activity, whereas oligomerization analysis indicates that activity loss does not simply correlate with tetramer disruption. The product-bound structure defines the catalytic pocket and a membrane-facing tunnel that suggests a possible route for LPA access, while electrophysiological recordings detected no PLPP1-associated ion conductance under the conditions tested. Together, these findings provide a structural framework for PLPP1 tetramer assembly, lipid phosphate hydrolysis, and product recognition.
- 17 September 2026
- Published by Springer Nature in Nature Plants
- Vol. 12 (9) , 1769-1781
Cross-ribbon conformation defines peptide recognition in SCREW/CTNIP–NUT/HSL3 signalling
Plants balance gas exchange with pathogen defense through dynamic stomatal regulation. Stomata close temporarily during pathogen attack to limit invasion, then reopen to restore photosynthesis and transpiration while lowering apoplast water saturation to inhibit pathogen proliferation. The secreted peptides, SCREW/CTNIP promote stomatal reopening through the receptor NUT/HSL3 and co-receptor BAK1/SERK3, thereby counteracting ABA and MAMP-triggered stomatal closure. Here we present the cryo-EM structures of AtNUTECD and the AtNUTECD–SCREW2/CTNIP4–AtBAK1ECD complex, uncovering a distinctive peptide–receptor interaction mechanism. SCREW2 adopts a unique cross-ribbon conformation that distinguishes it from other known conformations of LRR-RK-binding peptides, enabling its specific recognition by AtNUT and subsequent recruitment of AtBAK1. An N-linked glycan at N449 within the SCREW2–AtNUT binding interface is required for efficient SCREW2 recognition. Mutations in SCREW2 recognition sites significantly attenuated downstream MAPK activation and PTI marker gene expression.
- 17 September 2026
- Published by Springer Nature in Nature Plants
- Vol. 12 (9) , 1769-1781
Cross-ribbon conformation defines peptide recognition in SCREW/CTNIP–NUT/HSL3 signalling
Plants balance gas exchange with pathogen defense through dynamic stomatal regulation. Stomata close temporarily during pathogen attack to limit invasion, then reopen to restore photosynthesis and transpiration while lowering apoplast water saturation to inhibit pathogen proliferation. The secreted peptides, SCREW/CTNIP promote stomatal reopening through the receptor NUT/HSL3 and co-receptor BAK1/SERK3, thereby counteracting ABA and MAMP-triggered stomatal closure. Here we present the cryo-EM structures of AtNUTECD and the AtNUTECD–SCREW2/CTNIP4–AtBAK1ECD complex, uncovering a distinctive peptide–receptor interaction mechanism. SCREW2 adopts a unique cross-ribbon conformation that distinguishes it from other known conformations of LRR-RK-binding peptides, enabling its specific recognition by AtNUT and subsequent recruitment of AtBAK1. An N-linked glycan at N449 within the SCREW2–AtNUT binding interface is required for efficient SCREW2 recognition. Mutations in SCREW2 recognition sites significantly attenuated downstream MAPK activation and PTI marker gene expression.
- 26 August 2026
- Published by Springer Nature in Nature
- Vol. 657 (8131) , 549-558
Primate-specific regulation of the human glycosphingolipid gatekeeper UGCG
- 26 August 2026
- Published by Springer Nature in Nature
- Vol. 657 (8131) , 549-558
Primate-specific regulation of the human glycosphingolipid gatekeeper UGCG
- Open Access
- 4 June 2026
- Published by Springer Nature in Cell Discovery
- Vol. 12 (1)
Structural basis for a central permeation pathway in the P2X1 receptor
The ion permeation pathway is a critical determinant of ion channel function and selectivity; however, the structural basis for ion permeation in the P2X1 receptor, an ATP-gated ion channel crucial for platelet activation, thrombosis, and male infertility, remains incompletely understood. Here, we present high-resolution cryo-electron microscopy (cryo-EM) structures of the P2X1 receptor, which reveal a central ion permeation pathway spanning the entire extracellular domain, complementing the existing paradigms of ion channel architecture for the P2X receptor family. Within this pathway, we identify specific sites that coordinate hydrated calcium ions, including an aspartate ring that acts as a selectivity filter at the apex of the central vestibule. We also discover that a small molecule, 3,5-bis(trifluoromethyl)aniline, binds at the top of the central vestibule and potently inhibits cation flux through this central permeation pathway. Our findings reveal a new inhibitor-binding site in the P2X1 receptor. These insights provide a structural framework for the rational design of subtype-specific P2X receptor inhibitors targeting the central vestibule.
- 4 June 2026
- Published by Springer Nature in Cell Discovery
- Vol. 12 (1)
Open AccessStructural basis for a central permeation pathway in the P2X1 receptor
The ion permeation pathway is a critical determinant of ion channel function and selectivity; however, the structural basis for ion permeation in the P2X1 receptor, an ATP-gated ion channel crucial for platelet activation, thrombosis, and male infertility, remains incompletely understood. Here, we present high-resolution cryo-electron microscopy (cryo-EM) structures of the P2X1 receptor, which reveal a central ion permeation pathway spanning the entire extracellular domain, complementing the existing paradigms of ion channel architecture for the P2X receptor family. Within this pathway, we identify specific sites that coordinate hydrated calcium ions, including an aspartate ring that acts as a selectivity filter at the apex of the central vestibule. We also discover that a small molecule, 3,5-bis(trifluoromethyl)aniline, binds at the top of the central vestibule and potently inhibits cation flux through this central permeation pathway. Our findings reveal a new inhibitor-binding site in the P2X1 receptor. These insights provide a structural framework for the rational design of subtype-specific P2X receptor inhibitors targeting the central vestibule.
- Open Access
- 14 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Rational design of a Kappa opioid receptor peptide agonist with attenuated β-arrestin signaling
Difelikefalin is an FDA-approved κ-opioid receptor (KOR) peptide agonist used to treat chronic pruritus. However, as a balanced agonist that activates both G protein and β-arrestin pathways, difelikefalin remains associated with undesirable side effects linked to β-arrestin signaling. Here, we report the cryo-EM structure of the difelikefalin-KOR-Gi complex, identifying Y320 7.43 as a key residue that is critical for signaling bias. Guided by this structural insight, we engineer beta01, a β-amino acid-substituted analog with potent G protein activation but minimal β-arrestin recruitment. In mouse models, beta01 retains robust antinociceptive and antipruritic efficacy while significantly reducing sedation and anxiety-like behaviors. Structural, molecular dynamics simulations and 2D 13 C-Met NMR analyses further reveal beta01 stabilizes a unique KOR conformation with an expanded intracellular cavity that disfavors β-arrestin binding. This work establishes a rational structure-based framework for designing safer and more effective GPCR-targeted therapeutics.
- 14 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessRational design of a Kappa opioid receptor peptide agonist with attenuated β-arrestin signaling
Difelikefalin is an FDA-approved κ-opioid receptor (KOR) peptide agonist used to treat chronic pruritus. However, as a balanced agonist that activates both G protein and β-arrestin pathways, difelikefalin remains associated with undesirable side effects linked to β-arrestin signaling. Here, we report the cryo-EM structure of the difelikefalin-KOR-Gi complex, identifying Y320 7.43 as a key residue that is critical for signaling bias. Guided by this structural insight, we engineer beta01, a β-amino acid-substituted analog with potent G protein activation but minimal β-arrestin recruitment. In mouse models, beta01 retains robust antinociceptive and antipruritic efficacy while significantly reducing sedation and anxiety-like behaviors. Structural, molecular dynamics simulations and 2D 13 C-Met NMR analyses further reveal beta01 stabilizes a unique KOR conformation with an expanded intracellular cavity that disfavors β-arrestin binding. This work establishes a rational structure-based framework for designing safer and more effective GPCR-targeted therapeutics.
- Open Access
- 23 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Author Correction: Structural insights into antagonist recognition by the vasopressin V2 receptor
- 23 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessAuthor Correction: Structural insights into antagonist recognition by the vasopressin V2 receptor
- Top Cited PapersOpen Access
- 13 February 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (7) , eaea9832
Structure-based design of an opioid receptor modulator for enhanced morphine analgesia
The alarming rates of deaths due to opioid overdose present an urgent need for safer opioid analgesics. Positive allosteric modulators (PAMs) of opioid receptors (ORs) offer a promising approach to enhance opioid efficacy while reducing risks of overdose. In this study, we unveil the selective mechanism of PAM modulation of the OR family through structure elucidation of the δ-opioid receptor and μ-opioid receptor (μOR) bound to orthosteric agonists and PAMs BMS986187 (BMS187) and BMS986122 (BMS122). In addition, we uncovered an unexpected but conserved allosteric site across the transmembrane helices TM2 to TM4 of ORs, occupied by BMS187 but not BMS122. Leveraging these structural insights, we designed 9-(5-(4-chlorophenyl)furan-2-yl)-3,3,6,6-tetramethyl-3,4,5,6,7,9-hexahydro-1 H -xanthene-1,8(2 H )-dione (MPAM-15), whose αβ cooperativity factor is 33-fold higher than BMS122 and threefold higher than BMS187, indicating markedly stronger positive allosterism. Animal studies demonstrate that MPAM-15 shows excellent brain penetration and enhances morphine-induced antinociception without exacerbating respiratory depression or constipation. Molecular dynamics simulations revealed that MPAM-15 promotes and stabilizes the conformational equilibrium of μOR toward the canonical active state, providing a mechanistic basis for its enhanced allosteric potency. These discoveries substantially advance our understanding of OR allosteric mechanism and pave the way for the structure-based development of allosteric opioid analgesics.
- 13 February 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (7) , eaea9832
Top Cited PapersOpen AccessStructure-based design of an opioid receptor modulator for enhanced morphine analgesia
The alarming rates of deaths due to opioid overdose present an urgent need for safer opioid analgesics. Positive allosteric modulators (PAMs) of opioid receptors (ORs) offer a promising approach to enhance opioid efficacy while reducing risks of overdose. In this study, we unveil the selective mechanism of PAM modulation of the OR family through structure elucidation of the δ-opioid receptor and μ-opioid receptor (μOR) bound to orthosteric agonists and PAMs BMS986187 (BMS187) and BMS986122 (BMS122). In addition, we uncovered an unexpected but conserved allosteric site across the transmembrane helices TM2 to TM4 of ORs, occupied by BMS187 but not BMS122. Leveraging these structural insights, we designed 9-(5-(4-chlorophenyl)furan-2-yl)-3,3,6,6-tetramethyl-3,4,5,6,7,9-hexahydro-1 H -xanthene-1,8(2 H )-dione (MPAM-15), whose αβ cooperativity factor is 33-fold higher than BMS122 and threefold higher than BMS187, indicating markedly stronger positive allosterism. Animal studies demonstrate that MPAM-15 shows excellent brain penetration and enhances morphine-induced antinociception without exacerbating respiratory depression or constipation. Molecular dynamics simulations revealed that MPAM-15 promotes and stabilizes the conformational equilibrium of μOR toward the canonical active state, providing a mechanistic basis for its enhanced allosteric potency. These discoveries substantially advance our understanding of OR allosteric mechanism and pave the way for the structure-based development of allosteric opioid analgesics.
- Open Access
- 4 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-10
Structural insights into antagonist recognition by the vasopressin V2 receptor
The vasopressin V2 receptor (V2R), a class A G protein-coupled receptor, is essential for regulating body water homeostasis. V2R antagonists have emerged as promising treatments for hyponatremia; however, the absence of structural information for antagonist-bound V2R hampers our understanding of antagonist recognition and the targeted design of V2R antagonists. In this study, we present two cryo-electron microscopy structures of inactive V2R bound to the clinically approved antagonists tolvaptan and conivaptan. Combined with functional analyses and molecular dynamic simulations, these structures reveal distinct binding poses: tolvaptan is deeply inserted within the binding pocket, whereas conivaptan is positioned at a shallower depth. Integrated analyses further define critical pharmacophoric features governing antagonist activity and unveil a TM7 helical conformation-dependent antagonism mechanism that is distinct from classical GPCR inactivation modes. Our findings deepen understanding of antagonist recognition and antagonism of V2R, providing a foundation for the development of V2R-targeted therapies.
- 4 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-10
Open AccessStructural insights into antagonist recognition by the vasopressin V2 receptor
The vasopressin V2 receptor (V2R), a class A G protein-coupled receptor, is essential for regulating body water homeostasis. V2R antagonists have emerged as promising treatments for hyponatremia; however, the absence of structural information for antagonist-bound V2R hampers our understanding of antagonist recognition and the targeted design of V2R antagonists. In this study, we present two cryo-electron microscopy structures of inactive V2R bound to the clinically approved antagonists tolvaptan and conivaptan. Combined with functional analyses and molecular dynamic simulations, these structures reveal distinct binding poses: tolvaptan is deeply inserted within the binding pocket, whereas conivaptan is positioned at a shallower depth. Integrated analyses further define critical pharmacophoric features governing antagonist activity and unveil a TM7 helical conformation-dependent antagonism mechanism that is distinct from classical GPCR inactivation modes. Our findings deepen understanding of antagonist recognition and antagonism of V2R, providing a foundation for the development of V2R-targeted therapies.
- Open Access
- 2 July 2025
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 15 (10) , 5231-5243
Divergent activation patterns of BRS3 revealed by two Chinese herb-derived agonists
- 2 July 2025
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 15 (10) , 5231-5243
Open AccessDivergent activation patterns of BRS3 revealed by two Chinese herb-derived agonists